Granular Corneal Dystrophy

Back

Background

Granular corneal dystrophy (GCD), an IC3D category 1 dystrophy, is an autosomal-dominant, bilateral, noninflammatory condition that results in deposition of discrete, irregularly shaped opacities in the cornea by adulthood. It specifically affects the middle portion of the cornea (stroma) and can eventually cause decreased vision and eye discomfort.

There are two clinically separate types: granular corneal dystrophy type 1 (classic type) and granular corneal dystrophy type 2 (Avellino corneal dystrophy), which tends to have fewer corneal deposits, potentially resembling a combination of lattice corneal dystrophy and granular corneal dystrophy. Severe cases of granular dystrophy can be treated with either excimer laser ablation or by replacing cornea (corneal transplant). An example is shown in the image below.



View Image

Granular dystrophy. Image courtesy of James J Reidy, MD, FACS, Associate Professor of Ophthalmology, State University of New York, School of Medicine ....

Pathophysiology

The cornea is the clear outer coat of the front of the eye. A dystrophy of the cornea is defined as a bilateral noninflammatory clouding of the cornea. Corneal dystrophies can be divided into 3 categories based on their location within the cornea, as follows: (1) anterior corneal dystrophies affect the corneal epithelium and may involve the Bowman layer, (2) stromal corneal dystrophies affect the central layer of cornea (the stroma), and (3) posterior corneal dystrophies involve the Descemet membrane and the endothelium. Granular corneal dystrophy is a stromal dystrophy, but the epithelium and Bowman layer may be affected in late disease.

The age of onset for most corneal dystrophies is before 20 years (exceptions include map-dot-fingerprint dystrophy and Fuchs corneal dystrophy). Most corneal dystrophies are inherited in a dominant pattern. Exceptions include macular corneal dystrophy, type-3 lattice dystrophy, and the autosomal-recessive form of congenital hereditary endothelial dystrophy.

Granular corneal dystrophy types I and II result from mutations in the TGFBI (BIGH3) gene.[1, 2] Depending on the specific mutation in the TGFBI gene, phenotypes of corneal dystrophy may differ.[3, 4]  R124H and R555W are mutation hotspots of the TGFBI gene.[5, 6] The R124H mutation of TGFBI is highly correlated with granular corneal dystrophy type 2 (GCD2). 

In a 2017 Chinese cohort study of 24 patients with clinically apparent granular corneal dystrophy, the R124H mutation was identified in 37.5% of cases; R555Q, 16.7%; R124L, 25%; R555W, 20.8%, and R124C, 0%. In 13 subjects with a positive family history of granular corneal dystrophy but no clinical signs of the disease, the mutation rate was 69.2%.[6]  

Two 2017 studies demonstrated that granular corneal dystrophy type 22 corneal fibroblasts were more susceptible to oxidative stress–induced cell death than were wild-type cells, suggesting that oxidative stress is involved in the corneal pathogenesis of granular corneal dystrophy type 2.[7]  Melatonin might have potential as a therapeutic agent by reducing endoplasmic reticulum (ER) stress.[8, 9]  

Extinguishing or shortening of the meibomian glands was also observed in patients with granular corneal dystrophy type 2.[10]

Epidemiology

Frequency

United States

Although granular corneal dystrophy type 2 is more common than granular corneal dystrophy type 1 in the United States, both are rare.

International

Granular corneal dystrophy is uncommon worldwide. Granular corneal dystrophy type 1 is more common in Europe, while granular corneal dystrophy type 2 is more prevalent in Japan, Korea, and the United States.[11]

Mortality/Morbidity

Corneal changes generally first become visible during the second decade of life, but vision may not be affected until the fourth to fifth decade of life. Eye pain from recurrent corneal erosions also can occur.

Sex

No sexual predilection has been reported.

Age

In granular corneal dystrophy type 1, corneal changes appear within the first decade of life but may not be visible until the second decade of life.[11] Visual acuity usually remains good until the fourth or fifth decade of life, once the opacities become confluent. Granular corneal dystrophy type 2 is usually diagnosed during early adulthood.[2]

Prognosis

The prognosis of granular corneal dystrophy is good, with symptomatic patients being eligible for either laser phototherapeutic keratectomy (PTK) or corneal transplant.

For granular corneal dystrophy type 1, recurrence occurred most rapidly after PTK (median, 2.7 years), deep anterior lamellar keratoplasty (DALK; median, 3.2 years), and anterior lamellar keratoplasty (ALK; median, 3.7 years). Recurrence was most delayed after penetrating keratoplasty (median, 13.7 years). All groups in this study achieved a similar median best corrected visual acuity (BCVA); 20/25-20/30).[12]

History

Patients with granular corneal dystrophy (GCD) may have decreased vision, photosensitivity, and/or eye pain (from recurrent corneal erosions). Visual acuity decreases with age. As the pattern of inheritance for this dystrophy is autosomal dominant, one of the parents of the patient likely also has granular corneal dystrophy.

Physical

Granular corneal dystrophy is characterized by bilateral formation of discrete, focal, white granular deposits in the anterior stroma of cornea with clear areas between these deposits. The granules are primarily located in the central cornea, with an absence of these deposits in the peripheral cornea. The deposits can resemble crushed breadcrumbs or snowflakes.

As patients advance in age, the deposits become larger and increase in number. Eventually, the intervening clear areas develop a mild-to-severe corneal haze. When there are clear spaces between the deposits, vision generally is not severely affected. However, over time, the clear spaces become opacified. This late opacification is usually much more superficial than the longstanding, dense white granules. Vision dramatically declines when the clear spaces opacify.

Causes

Granular dystrophy is an autosomal-dominant condition that affects the TGFBI (BIGH3) gene; its genetic defect has been mapped to chromosome 5q.

Complications

Complications of granular corneal dystrophy include loss of vision and recurrent corneal erosions.

Complications of recurrent erosions include corneal infection and scarring, which can lead to significant decreased vision.

Procedures

Corneal biopsy, which is not clinically indicated in patients with granular corneal dystrophy (GCD), reveals eosinophilic hyaline deposits in corneal stroma. When a corneal transplant is performed, the specimen is submitted for histopathologic evaluation

Optical coherence tomography (OCT) has been used in assessing granular corneal dystrophy[13] and has been used to guide phototherapeutic keratectomy (PTK).[14, 15, 16]

Histologic Findings

When corneal specimens are obtained, light microscopy reveals eosinophilic hyaline deposits in the corneal stroma; the source of hyaline material is still unknown.

Masson trichrome stains the deposits bright red.

Pathologic deposits react with antibodies to keratoepithelin.[2]

Medical Care

When recurrent erosions occur with granular corneal dystrophy (GCD), they are treated like any other form of recurrent erosions. Under care of an ophthalmologist, bandage contact lens along with antibiotic drops can be prescribed; alternatively, patching with an antibiotic ointment can be used. Some physicians treat recurrent erosions with frequent antibiotic ointments while awake.

Once the acute episode of recurrent erosions has resolved, preventive treatment may include sodium chloride 5% drops (eg, Muro 128) or artificial tear lubricating drops during the day and lubricating ointment at bedtime. If recurrent corneal erosions occur despite medical therapy, corneal punctures or excimer laser phototherapeutic keratectomy (PTK) may be considered.

Surgical Care

Excessive corneal erosions or visual decrease from superficial opacities can be treated with PTK. Excimer laser PTK removes superficial opacities, smooths the corneal surface, and allows the epithelium to re-adhere more tightly. When deep opacities are causing significant visual symptoms, corneal transplantation may be required.

If visual acuity worsens and most of the opacities are deep, lamellar or full-thickness corneal transplantation can be performed. Although the success rate for corneal transplantation is very high, granular deposits recur with time. Fortunately, when the deposits recur, they tend to be superficial, and amenable to treatment with excimer laser PTK. A study showed that multiple PTK procedures can be safely performed in grafts without compromising graft survival and with improved visual acuity.[17]

For cases in which all of these therapies fail, sutureless femtosecond laser-assisted anterior lamellar keratoplasty (FALK) is recommended as a safe and effective technique for the management of recurrent granular corneal dystrophy in post–penetrating keratoplasty and post-PTK eyes.[18]

Two long-term case reports have suggested that the simultaneous transplantation of healthy donor limbus when performing penetrating keratoplasty (ie, limbo-keratoplasty) may prolong recurrence in granular corneal dystrophy.[19]

Long-Term Monitoring

Patients with corneal epithelial defects due to recurrent erosions need to be observed every few days to make certain the defect is healing.

Inpatient & Outpatient Medications

Patients with corneal epithelial defects from recurrent erosions require treatment with topical antibiotics to prevent infection.

Medication Summary

Medical therapy for recurrent corneal erosions includes hypertonic saline, which is believed to increase adherence of epithelium to the underlying stroma. Lubrication, especially at bedtime, also may help prevent further corneal erosions.

Sodium chloride hypertonic, ophthalmic (Adsorbonac, Afrin Saline Mist, Muro 128)

Clinical Context:  Used for temporary relief of corneal edema.

Class Summary

This agent dehydrates the epithelium, allowing it to better adhere to underlying stroma.

Artificial tears (Celluvisc, Murine, Refresh, GenTeal, Refresh PM, Lacri-Lube)

Clinical Context:  Contains equivalent of 0.9% NaCl and are used to maintain ocular tonicity. Acts to stabilize and thicken precorneal tear film and prolong tear film breakup time, which occurs with dry eye states.

Class Summary

These agents can moisten ocular surface and decrease the frequency of recurrent erosions.

Author

Jean Deschênes, MD, FRCSC, Professor, Research Associate, Director, Uveitis Program, Department of Ophthalmology, McGill University Faculty of Medicine; Senior Ophthalmologist, Clinical Director, Department of Ophthalmology, Royal Victoria Hospital, Canada

Disclosure: Nothing to disclose.

Coauthor(s)

Susan Ruyu Qi , University of Montreal Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, AAO, OMIC, Avedro; Bio-Tissue; GSK, Kala, Novartis; Shire; Sun Ophthalmics; TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Avedro; Bio-Tissue; Shire<br/>Received income in an amount equal to or greater than $250 from: AAO, OMIC, Avedro; Bio-Tissue; GSK, Kala, Novartis; Shire; Sun Ophthalmics; TearLab.

Chief Editor

Hampton Roy, Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Disclosure: Nothing to disclose.

Joanne W Ho, University of California, San Diego, School of Medicine

Disclosure: Nothing to disclose.

Natalie A Afshari, MD, MA, FACS, Stuart I Brown, MD, Chair in Ophthalmology In Memory of Donald P Shiley, Professor of Ophthalmology, Chief of Cornea and Refractive Surgery, Director of Education, Fellowship Program Director in Cornea and Refractive Surgery, Shiley Eye Center, University of California, San Diego, School of Medicine

Disclosure: Nothing to disclose.

William B Trattler, MD, Ophthalmologist, The Center for Excellence in Eye Care; Volunteer Assistant Professor of Ophthalmology, Bascom Palmer Eye Institute

Disclosure: Received consulting fee from Allergan for consulting; Received consulting fee from Alcon for consulting; Received consulting fee from Bausch & Lomb for consulting; Received consulting fee from Abbott Medical Optics for consulting; Received consulting fee from CXLUSA for none; Received consulting fee from LensAR for none.

William Lloyd Clark, MD, Palmetto Retina

Disclosure: Nothing to disclose.

References

  1. Grunauer-Kloevekorn C, Brautigam S, Wolter-Roessler M. Molecular genetic analysis of the BIGH3 gene in lattice type I (Biber-Haab-Dimmer) and granular type II (Avellino) corneal dystrophy: is indirect mutation analysis for hot spots recommended?. Klin Monatsbl Augenheilkd. 2005 Dec. 222(12):1017-23. [View Abstract]
  2. Weiss JS, Møller HU, Lisch W, Kinoshita S, Aldave AJ, Belin MW, et al. The IC3D classification of the corneal dystrophies. Cornea. 2008 Dec. 27 Suppl 2:S1-83. [View Abstract]
  3. Choi SI, Kim BY, Dadakhujaev S, Oh JY, Kim TI, Kim JY, et al. Impaired autophagy and delayed autophagic clearance of transforming growth factor ß-induced protein (TGFBI) in granular corneal dystrophy type 2. Autophagy. 2012 Sep 20. 8(12):[View Abstract]
  4. Cho KJ, Mok JW, Na KS, Rho CR, Byun YS, Hwang HS, et al. TGFBI gene mutations in a Korean population with corneal dystrophy. Mol Vis. 2012. 18:2012-21. [View Abstract]
  5. Kannabiran C, Klintworth GK. TGFBI gene mutations in corneal dystrophies. Hum Mutat. 2006 Jul. 27 (7):615-25. [View Abstract]
  6. Zeng L, Zhao J, Chen Y, Zhao F, Li M, Chao-Shern C, et al. TGFBI Gene Mutation Analysis of Clinically Diagnosed Granular Corneal Dystrophy Patients Prior to PTK: A Pilot Study from Eastern China. Sci Rep. 2017 Apr 4. 7 (1):596. [View Abstract]
  7. Choi SI, Kim TI, Kim KS, Kim BY, Ahn SY, Cho HJ, et al. Decreased catalase expression and increased susceptibility to oxidative stress in primary cultured corneal fibroblasts from patients with granular corneal dystrophy type II. Am J Pathol. 2009 Jul. 175 (1):248-61. [View Abstract]
  8. Choi SI, Lee E, Akuzum B, Jeong JB, Maeng YS, Kim TI, et al. Melatonin reduces endoplasmic reticulum stress and corneal dystrophy-associated TGFBIp through activation of endoplasmic reticulum-associated protein degradation. J Pineal Res. 2017 Oct. 63 (3):[View Abstract]
  9. Ahn JH, Kim HD, Abuzar SM, Lee JY, Jin SE, Kim EK, et al. Intracorneal melatonin delivery using 2-hydroxypropyl-β-cyclodextrin ophthalmic solution for granular corneal dystrophy type 2. Int J Pharm. 2017 Aug 30. 529 (1-2):608-616. [View Abstract]
  10. Sakimoto T. Granular corneal dystrophy type 2 is associated with morphological abnormalities of meibomian glands. Br J Ophthalmol. 2015 Jan. 99 (1):26-8. [View Abstract]
  11. Klintworth GK. Corneal dystrophies. Orphanet J Rare Dis. 2009 Feb 23. 4:7. [View Abstract]
  12. Lewis DR, Price MO, Feng MT, Price FW Jr. Recurrence of Granular Corneal Dystrophy Type 1 After Phototherapeutic Keratectomy, Lamellar Keratoplasty, and Penetrating Keratoplasty in a Single Population. Cornea. 2017 Oct. 36 (10):1227-1232. [View Abstract]
  13. Mori H, Miura M, Iwasaki T, et al. Three-dimensional optical coherence tomography-guided phototherapeutic keratectomy for granular corneal dystrophy. Cornea. 2009 Sep. 28(8):944-7. [View Abstract]
  14. Dalton K, Schneider S, Sorbara L, Jones L. Confocal microscopy and optical coherence tomography imaging of hereditary granular dystrophy. Cont Lens Anterior Eye. 2009 Nov 27. [View Abstract]
  15. Ashar JN, Latha M, Vaddavalli PK. Phototherapeutic keratectomy versus alcohol epitheliectomy with mechanical debridement for superficial variant of granular dystrophy: A paired eye comparison. Cont Lens Anterior Eye. 2012 Oct. 35(5):236-9. [View Abstract]
  16. Jung SH, Han KE, Stulting RD, Sgrignoli B, Kim TI, Kim EK. Phototherapeutic Keratectomy in Diffuse Stromal Haze in Granular Corneal Dystrophy Type 2. Cornea. 2012 Apr 21. [View Abstract]
  17. Rathi VM, Taneja M, Murthy SI, Bagga B, Vaddavalli PK, Sangwan VS. Phototherapeutic keratectomy for recurrent granular dystrophy in postpenetrating keratoplasty eyes. Indian J Ophthalmol. 2016 Feb. 64 (2):140-4. [View Abstract]
  18. Taneja M, Rathi VM, Murthy SI, Bagga B, Vaddavalli PK. Femtosecond Laser-Assisted Anterior Lamellar Keratoplasty for Recurrence of Granular Corneal Dystrophy in Postkeratoplasty Eyes. Cornea. 2017 Mar. 36 (3):300-303. [View Abstract]
  19. Lang SJ, Eberwein P, Reinshagen H, Reinhard T, Sundmacher R. Simultaneous transplantation of limbal stem cells may reduce recurrences of granular dystrophy after corneal transplantation: 2 long-term case reports. Medicine (Baltimore). 2015 May. 94 (20):e789. [View Abstract]
  20. Das S, Langenbucher A, Seitz B. Excimer laser phototherapeutic keratectomy for granular and lattice corneal dystrophy: a comparative study. J Refract Surg. 2005 Nov-Dec. 21(6):727-31. [View Abstract]
  21. Albert D, Jakobiec F. Principles and Practice of Ophthalmology. 1994. Vol 1: 26-49.
  22. Jung SH, Han KE, Sgrignoli B, Kim TI, Lee HK, Kim EK. Intraocular lens power calculations for cataract surgery after phototherapeutic keratectomy in granular corneal dystrophy type 2. J Refract Surg. 2012 Oct. 28(10):714-24. [View Abstract]
  23. Klintworth GK. Advances in the molecular genetics of corneal dystrophies. Am J Ophthalmol. 1999 Dec. 128(6):747-54. [View Abstract]
  24. Krachmer J. Cornea. Vol 2: 1996.
  25. Yamamoto S, Okada M, Tsujikawa M, et al. The spectrum of beta ig-h3 gene mutations in Japanese patients with corneal dystrophy. Cornea. 2000 May. 19(3 Suppl):S21-3. [View Abstract]

Granular dystrophy. Image courtesy of James J Reidy, MD, FACS, Associate Professor of Ophthalmology, State University of New York, School of Medicine & Biomedical Sciences, Buffalo, New York.

Granular dystrophy. Image courtesy of James J Reidy, MD, FACS, Associate Professor of Ophthalmology, State University of New York, School of Medicine & Biomedical Sciences, Buffalo, New York.

The slit lamp parallelipid demonstrates the deposition of opacities throughout the central stroma.